Scinai Immunotherapeutics
Naama Adi-Hen, Ph.D., is a seasoned professional in the biopharmaceutical industry currently serving as the Head of Quality Assurance at Scinai Immunotherapeutics Ltd. since May 2022, where responsibilities include ensuring the quality of innovative biological products for autoimmune and infectious diseases. Prior experience includes serving as Director of Quality Assurance and Quality Control at BioNanoSim from April 2016 to May 2022, and Project Manager at Silenseed from January 2012 to March 2016. Naama also contributed to academia at the Hebrew University of Jerusalem - Hadassah, teaching courses in Pharmacy from 2002 to 2012. Educational qualifications include a Doctor of Pharmacy (PharmD) with a focus on Pharmaceutics and Drug Design, a Master of Science in Medicinal and Pharmaceutical Chemistry, and a Bachelor of Science in Chemistry, all obtained from The Hebrew University of Jerusalem.
This person is not in any offices
Scinai Immunotherapeutics
1 followers
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com